2008: Pediatric SLE, Myositis, Scleroderma & Autoinflammatory Syndromes
Search or Browse by Day

Pediatric SLE, Myositis, Scleroderma & Autoinflammatory Syndromes

Sunday, October 26, 2008
212
Combined Spanish Cohort and International Blau Syndrome Registry: Report on the Expanding Phenotype of Patients with NOD-2 Mutation
213
Prospective Validation Of The Diagnostic Score For Molecular Analysis Of Hereditary Autoinflammatory Syndromes In Children With Periodic Fever
214
Evidences for the need of new Diagnostic Criteria for PFAPA syndrome
215
Height and Weight Development Following Cyclical Intravenous Pamidronate in Children and Adolescents with Chronic Recurrent Multifocal Osteomyelitis (CRMO)
216
Successful Use of Anakinra, a Soluble Interleukin 1 Receptor Antagonist in Pediatric Rheumatic Diseases Associated Macrophage Activation Syndrome
217
IL-1 Antagonism for Treatment of Macrophage Activation Syndrome
218
Three Patients with Systemic Juvenile Idiopathic Arthritis (sJIA) Who Developed Acute Liver Failure While Taking Anakinra: Drug Reaction vs MAS
219
Consensus Development of a Corticosteroid (CS) Tapering Algorithm for the Randomized Placebo Phase Study of Rilonocept in the Treatment of Systemic JIA (RAPPORT)
220
Anti-NR-2 Antibodies are Stable over Time in Childhood-onset SLE (cSLE) Patients with Neurocognitive Dysfunction
221
Neurocognitive Dysfunction is Prevalent in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
222
Longitudinal Performance on the Pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM) in childhood-onset Systemic Lupus Erythematosus (cSLE)
223
Vitamin D Deficiency and Interferon Alpha Signature in Childhood-onset Systemic Lupus Erythematosus (cSLE)
224
Cognitive Impairment in Children with Systemic Lupus Erythematosus: Assessing Diagnostic Practices, and Research Needs in the CARRA Network
225
Minimal Clinically Important Difference (MCID) of SLE Disease Activity Measures When Used In Childhood Systemic Lupus Erythematosus (cSLE)
226
Mortality in Pediatric Patients with End Stage Renal Disease (ESRD) secondary to Systemic Lupus Erythematosus (SLE)
227
Increased Mortality Risk Associated with Systemic Lupus Erythematosus (SLE) in Pediatric vs. Adult End Stage Renal Disease (ESRD) Patients
228
Monocytes in the Urine of Children with Lupus; A Potential Marker of Active Nephritis
229
Retrospective Analysis of Neurocognitive Testing in Children and Adolescents with SLE
230
Clinical Laboratory Markers of Cardiovascular Risk in a Pediatric SLE Cohort
231
Longitudinal Study of Vascular Markers of Premature Atherosclerosis in Pediatric Systemic Lupus Erythematosus
232
Clinical Features of Pre-Pubertal Onset Systemic Lupus Erythematosus in Girls
233
Michigan Lupus Epidemiology & Surveillance (MILES) Program: Features of SLE in a population-based registry of pediatric-onset patients
234
Rheumatic Features Associated with Autoimmune Hepatitis in Children
235
Risk Factors for Symptomatic Avascular Necrosis in Pediatric Systemic Lupus Erythematosus (pSLE)
236
Longitudinal Analysis of Vitamin D Deficiency in Pediatric Lupus
237
Diversity of treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment study
238
Normal Nailfold End Row Loops are Associated with a Shorter Duration of Untreated Disease in Children with Juvenile Dermatomyositis
239
Bone Mineral Density (BMD) and Associations with Body Mass, Disease Severity and Medication Use in Juvenile Dermatomyositis (JDM)
240
Low Bone Mass in Juvenile Onset Sclerosis Systemic: a possible role for low 25-Hydroxyvitamin D
241
Development of Localized Scleroderma Outcome Measurement: A Pilot Study of Global Assessments
242
Localized Scleroderma Cutaneous Assessment Tool: A Proof-of-concept Study of LS Skin Damage Index (LoSDI)
243
Life-threatening Pulmonary Hypertension (PH) and Alveolar Proteinosis (AP) in Systemic JIA (SJIA)
244
Poor Bone Mineral Density Already Present in Newly Diagnosed Juvenile Systemic Lupus Erythematosus Patients
245
Assessment of An Ultrasound Disease Activity (US DA) Measure for Localized Scleroderma (LS)
246
Quality of Life in Children and Adolescents with Juvenile Localized Scleroderma
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>